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Recent evidence suggests that many members of the human kallikrein gene family are differentially regulated in breast cancer and
other endocrine-related malignancies. In this study, we utilised the serial analysis of gene expression (SAGE) and expressed sequence
tag (EST) databases of the Cancer Genome Anatomy Project (CGAP) to perform in silico analyses of the expression pattern of the
15 human kallikrein genes in normal and cancerous breast tissues and cell lines using different analytical tools such as Virtual Northern
blotting, Digital Differential Display and X-profiler. Our results indicate that at least four kallikrein genes (KLK5, 6, 8, 10) are
downregulated in breast cancer. Probing eight normal and 24 breast cancer SAGE libraries with gene-specific tags for each of the
above kallikreins indicated moderate-to-high expression densities in normal breast (27–319 tags per million; tpm, in two to five out
of eight libraries), compared to no or low expression (0 – 34tpm in zero to two libraries out of 24) in breast cancer. These data
were verified by screening the EST databases, where all mRNA clones isolated for these genes, except for one in each, were from
normal breast libraries, with no clones detected from breast cancer tissues or cell lines (with the exception of KLK8). X-profiler
comparison of two pools of normal and breast cancer libraries further verified the presence of significant downregulation of
expression levels of 4 of the kallikreins genes (KLK5, 6, 10, 12). We experimentally verified the downregulation of these four
kallikreins (KLK5, 6, 8, 10 and 12) by RT – PCR analysis.
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Cancer is fundamentally a disease of the genome. A key
component in understanding the nature of cancer is the
identification of those genes that are directly involved in or are
associated with malignancy. In the past two decades, much
progress has been made in identifying genes that play direct roles
in the development of cancer. The Cancer Genome Anatomy
Project (CGAP) aims to catalog all genes expressed during cancer
development. Knowledge of these genes can then be utilised to
understand the pathogenesis of cancer, to define its molecular
signatures and to develop biomarkers for early detection and
targets for intervention (Strausberg, 2001).
The Cancer Genome Anatomy Project focused on a strategy for
gene identification based on isolation of mRNAs from tissues and
generation of libraries from these transcripts. This library of genes,
expressed in normal and cancer cells, has been developed through
the application of two approaches; the expressed sequence tag
(EST) (Adams et al, 1993) and the serial analysis of gene
expression (SAGE) (Velculescu et al, 1995). The SAGE method is
similar to the EST approach, in that it provides a sequence tag for a
portion of a cDNA. In this approach, the tagged sequences are
generally quite short (10–14bp) and the individual tags are
annealed to generate DNA molecules carrying many individual
tags. Therefore, each DNA sequencing read generates tags for
multiple transcripts. This method has been shown to quantitatively
assess transcript levels and is more efficient than traditional EST
sequencing. Thus, the opportunity to identify rarely expressed
transcripts is increased in the SAGE approach.
Kallikreins are a family of 15 genes clustered together on
chromosome 19 (Yousef and Diamandis, 2001, 2003) and encode
for serine protease enzymes (Clements et al, 2001; Yousef and
Diamandis, 2002b). Prostate-specific antigen (PSA, hK3), a
member of this family, is an established tumour marker for
prostate cancer (Barry, 2001). Prostate-specific antigen SA was
recently found to be expressed in the female breast and might have
a prognostic value in breast cancer (Black and Diamandis, 2000).
Furthermore, other kallikreins were also found to have prognostic
value in breast and other endocrine malignancies (Liu et al, 1996;
Tanimoto et al, 1999; Yousef et al, 2000a; Benson et al, 2002;
Diamandis and Yousef, 2002; Yousef and Diamandis, 2002a, 2003;
Diamandis et al, 2003; Luo et al, 2003).
In this study, we used an in silico analysis approach to examine
kallikrein gene expression in normal and cancerous breast tissues
and cell lines. We provide evidence that at least four kallikreins
are downregulated in breast cancer, and experimentally verified
the downregulation of of these kallikreins (KLK5 and KLK12)
by RT – PCR.
MATERIALS AND METHODS
Serial Analysis of gene expression (SAGE)
All publicly available SAGE data until August 2003 were used
for analysis of kallikrein gene expression. We obtained a reliable
mapping of UniGene (http://www.ncbi.nlm.nih.gov/UniGene/)
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ygroups to both NlaIII and Sau3A tags from the Serial Analysis of
Gene Expression Tag to Gene Mapping (SAGEmap) search tool
available through the NCBI web site (http://www.ncbi.nlm.nih.gov/).
Each UniGene group consists of all GenBank sequences represent-
ing the same human gene. Hereafter, each such group is referred
to as a ‘gene’. Tags mapping to more than one kallikrein were
excluded.
Virtual Northern blots (VNB)
The mRNA sequences of the 15 human kallikrein genes were used
to identify unique sequence tags of UniGene clusters for each
kallikrein (the GenBank reference sequences were used). Two
restriction digestion enzymes were used (NlaIII, Sau3A). These
sequence tags were then used to determine the levels of expression
of different kallikreins in eight normal (six tissues and two cell
lines) and 24 breast cancer (12 tissues and 12 cell lines) libraries.
Detailed information of these libraries is available from the website
of CGAP (http://www.ncbi.nlm.nih.gov/ncicgap/). Analyses were
carried out by comparing the proportion of libraries of each type
(normal vs cancer) that show the expression of each tag in addition
to the average expression densities in these libraries. mRNA
sequences from the Human Genome Project were used as reference
sequences. If more than one tag of the same gene appears in the
same library, we only included the one with the highest expression
(maximum tpm); the other tag was excluded to avoid inaccurate
estimation of expression. Expression levels are displayed as blots
with different densities and corrected as tpm to facilitate
comparison. Table 1 shows the tags and UniGene clusters used
for each gene to probe the GCAP libraries.
Expressed sequence tag (EST) analysis
The full-length mRNA sequence of each kallikrein was compared
against the human EST databases of the NCBI. At the time of the
study, these databases included seven normal and 14 breast cancer
libraries. Expression was calculated for each kallikrein as the
number of positive libraries out of the total in each tissue type, in
addition to the total number of clones detected in each type.
X-profiler analysis
X-profiler analyses of kallikrein gene expression were performed
by comparing normal and breast cancer libraries available in the
SAGE databases. As expression levels of various kallikreins might
be different from one cell line to another and in different types of
breast cancer, we compared a pool of eight normal breast libraries
(from tissues and cell lines) against 24 breast cancer libraries from
tissues and cell lines. The X-profiler cut-off value was set at two-
fold difference.
Digital differential display (DDD) analysis
The DDD search engine (Strausberg et al, 2001) was used to
compare EST expression in normal and cancer libraries. The
databases at the time of analysis included seven normal and 14
breast cancer libraries. Libraries with less than 25 clones were
excluded from the analysis.
Normal and malignant breast tissues
Normal breast tissues were obtained from four women undergoing
reduction mammoplasties. Breast tumour tissues were obtained
from 14 female patients at participating hospitals of the Ontario
Provincial Steroid Hormone Receptor Program. The normal and
tumour tissues were immediately frozen in liquid nitrogen after
surgical resection and stored in this manner until extracted. The
tissues were pulverised with a hammer under liquid nitrogen and
RNA was extracted as described below. Our protocols were
approved by the Institutional Review Board of the University of
Toronto.
Reverse transcriptase polymerase chain reaction
(RT – PCR)
Total RNA was extracted from the cell lines or tissues using Trizol
reagent (Gibco BRL) following the manufacturer’s instructions.
RNA concentration was determined spectrophotometrically. Total
RNA (2mg) was reverse-transcribed into first-strand cDNA
using the Superscriptt preamplification system (Gibco, BRL,
Gaithersburg, MD). The final volume was 20ml. Two gene-specific
primers were designed for each kallikrein (Table 2), and PCR was
carried out in a reaction mixture containing 1ml of cDNA, 10mM
Tris-HCl (pH 8.3), 50mM KCl, 1.5mM MgCl2, 200mM dNTPs
(deoxynucleoside triphosphates), 150ng of primers and 2.5U of
AmpliTaq Gold DNA polymerase (Roche Molecular Systems,
Branchburg, NJ, USA) on a Perkin-Elmer 9600 thermal cycler.
The cycling conditions were 941C for 15min followed by 40 cycles
of 941C for 30s, annealing for 1min (Table 2) and a final extension
step at 631C for 10min. Equal amounts of PCR products were
Table 1 Gene-specific SAGE tags used to probe different libraries of the
CGAP databases
Kallikrein Restriction enzyme SAGE tags Unigene cluster
KLK3 NlaIII GGATGGGGAT Hs.171995
GTGACACAGC
Sau3A CACACTGAGA Hs.171995
ACGCTTTTGT
KLK5 NlaIII TCTCCTGGAC Hs.50915
Sau3A CAGGAAACCA Hs.50915
KLK6 NlaIII CACTCAATAA Hs.79361
Sau3A CAAAAAACCA Hs.79361
KLK8 NlaIII GTCTGTGCAG Hs.104570
Sau3A TCCCTTAATA Hs.104570
KLK10 NlaIII TAAGGCTTAA Hs.69423
Sau3A CAGATGCCCA Hs.69423
KLK11 NlaIII GTGTGTGCCA Hs.57771
Sau3A CAGGAGACGA Hs.57771
KLK12 NlaIII AGGAACAACT Hs.159679
Sau3A ATGAGGAACA Hs.159679
Only kallikreins that showed differential expression are shown in this table.
Table 2 Primers and conditions used for PCR analysis
Gene Sequence
a
Product
length
b Ta
c
Number
of cycles
KLK5 GTCACCAGTTTATGAATCTGGGC 328 60 35
GGCGCAGAACATGGTGTCATC
KLK6 GAAGCTGATGGTGGTGCTGAGTCTG 454 60 35
GTCAGGGAAATCACCATCTGCTGTC
KLK8 GCCTTGTTCCAGGGCCAGC 416 65 35
GCATCCTCACACTTCTTCTGGG
KLK10 GGAAACAAGCCACTGTGGGC 468 60 35
GAGGATGCCTTGGAGGGTCTC
KLK12 GAGCAGATCCGGCACAGCGG 425 69 35
TCTTGTCCACAGGGCCCCACAG
GGCAGGGCGCAGCGCTCC
KLK15 CTACGGACCACGTCTCGGGTC 459 65 35
GACACCAGGCTTGGTGGTGTTG
b-actin ATCTGGCACCACACCTTCTA 835 62 35
CGTCATACTCCTGCTTGCTG
aAll sequences are mentioned from the 50 to 30 direction.
bIn base pairs.
cAnnealing
temperature.
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bromide staining. All primers for RT – PCR spanned at least two
exons to avoid contamination by genomic DNA. Expression of the
house-keeping gene (actin) was examined at the same experi-
mental conditions for each kallikrein, but the gel was run
separately.
To verify the identity of the PCR products, they were cloned into
the pCR 2.1-TOPO vector (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s instructions. The inserts were
sequenced from both directions using vector-specific primers, with
an automated DNA sequencer. Each experiment was confirmed at
least twice and the results were shown to be consistent.
RESULTS
Serial analysis of gene experssion and VNB for kallikrein
expression in breast cancer
As shown in Table 3, seven kallikreins were found to be down-
regulated in breast cancer compared to normal breast tissues and
cell lines. Probing all breast libraries from different sources
(cancerous and normal tissues and cell lines) with KLK5-specific
probes revealed that while KLK5 was detectable in five out of eight
normal breast libraries with moderate-to-high density (average
expression of 319tpm), mRNA tags were detectable in only one out
of 24 cancer libraries. This library is a ‘carcinoma in situ’ and
showed 34 tpm expression level. KLK6-specifc tags were also
detectable in three out of eight normal libraries with high density
(average 270tpm) and in only two cancer libraries (out of 24) with
low average expression level (15tpm). KLK8 showed a generally
lower expression in normal breast (average 27tpm). However,
expression was undetectable in the 24 cancer libraries screened.
Moderate KLK10 expression levels (average 85tpm) were detected
in four out of eight normal breast tissues, but expression was
undetectable in all cancer libraries tested. Slightly higher expres-
sion levels were detected for KLK11 and KLK12 in normal breast
compared to cancer, although not statistically conclusive (Table 3).
It is worth mentioning, however, that the only cancer library where
KLK11 was detected was described in the database as ‘Low grade
malignancy, with some in situ component’. The results for KLK3
were inconclusive, as low expression was detected in only one
normal library, but not in cancer libraries (Table 3). A low number
of KLK1 and KLK13 mRNA messages were detectable in the MCF7
breast cancer cell line 3h after oestradiol stimulation (16tpm for
each gene), but not in unstimulated cells (data not shown). No
significant change of expression levels was detected in the ZR-75
breast cancer cell line when stimulated by oestrogen (data not
shown).
Analysis of kallikrein gene expression utilising EST
databases
Our EST library screening results (Table 4) were consistent with
SAGE expression and VNB data. While very few EST clones were
retrieved from the 14 EST cancer libraries (nine for KLK8, two for
KLK3, and one for each of the rest), EST clones were much more
detectable in normal libraries. In all, 25 KLK5 EST clones were
detected in three out of eight normal breast libraries. KLK6 showed
higher expression levels; 32 EST clones were found in five out of
eight libraries screened. Totally, 25 KLK10 EST clones were
detected in five out of eight normal libraries, and 14 clones were
positive for KLK8 in two out of eight normal libraries. Two EST
clones for KLK3 were detected in breast cancer. It should be
emphasised, however, that EST figures are more useful as
‘qualitative’ data. Quantitative EST results are only approximate
and cannot be relied upon, due to the fact that some EST libraries
are normalised. No other kallikreins were found to be differentially
expressed in breast cancer using SAGE or EST databases.
X-profiler and DDD analysis of kallikrein gene expression
in the breast
Table 5 shows the analysis of kallikrein gene expression in normal
and cancerous breast tissues utilising the ‘X-profiler’ analysis
tool. A pool of eight normal breast tissues and cell lines was
compared to a second pool of 24 breast cancer tissues and cell lines
Table 3 In silico analysis of kallikrein gene expression in normal and
breast cancer tissues and cell lines screened by SAGE database
Kallikrein Library Positivity (%) Average density
a
KLK3 Normal breast 1/8 (13) 26
Breast cancer 0/24 (0) 0
KLK5 Normal breast 5/8 (62) 319
Breast cancer 1/24 (4) 34
KLK6 Normal breast 3/8 (37) 270
Breast cancer 2/24 (8) 15
KLK8 Normal breast 2/8 (25) 27
Breast cancer 0/24 (0) 0
KLK10 Normal breast 4/8 (50) 85
Breast cancer 0/24 (0) 0
KLK11 Normal breast 3/8 (37) 40
Breast cancer 1/24 (4) 28
KLK12 Normal breast 1/8 (13) 15
Breast cancer 0/24 (0) 0
aTags per million (tpm).
Table 4 In silico analysis of kallikrein gene expression in normal and
cancerous breast tissues and cell lines based on the EST databases
Kallikrein Library type Positivity
Number
of clones
KLK3 Normal breast 0/7 0
Breast cancer 1/14 2
KLK5 Normal breast 3/8 25
Breast cancer 1/14 1
KLK6 Normal breast 5/8 32
Breast cancer 1/14 1
KLK8 Normal breast 2/8 14
Breast cancer 1/14 9
KLK10 Normal breast 5/8 25
Breast cancer 1/14 1
KLK11 Normal breast 2/8 10
Breast cancer 0/14 0
KLK12 Normal breast 1/8 2
Breast cancer 0/14 0
Table 5 X-Profiler analysis of kallikrein gene expression in normal and
cancerous breast tissues and cell lines
Gene expression counts
Kallikrein Cancer
a Normal
b Difference factor
c
KLK5 2 7 0.797
KLK6 2 6 0.716
KLK10 0 6 0.877
KLK12 2 4 0.719
aA pool of 22 breast cancer SAGE libraries.
bA pool of seven normal breast SAGE
libraries.
cA factor of one represents the highest statistical significance.
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differences in the expression levels of four kallikreins in breast
cancer compared to normal. KLK5, 6, 10 and 12 were all
downregulated in cancer compared to normal. The most
significant result was obtained for KLK10 (difference factor of
0.877).
No statistically significant differences were detected by the DDD,
except for KLK3, where a 10-fold increase was found in cancer
when comparing the pool of normal and breast cancer libraries.
Evaluation of the in silico analysis
We verified the reliability of the in silico analysis with previously
published reports on kallikrein expression in normal tissues
(Yoshida et al, 1998; Yousef and Diamandis, 2000, 2003; Yousef
et al, 2001, 2000b, 2000d). These results were in general agreement
with PCR and Northern blotting data (Gan et al, 2000; Clements
et al, 2001; Yousef and Diamandis, 2001). For example, our SAGE
and EST data indicate that KLK2-4 are highly expressed in the
prostate, while KLK5 is highly expressed in normal breast tissue
and skin, in agreement with published experimental reports
(Brattsand and Egelrud, 1999; Yousef and Diamandis, 1999). In
addition, we found that those kallikreins that show differential
expression in breast cancer have similar levels of expression in
normal and cancer tissues in other malignancies (data not shown),
further verifying the specificity of our results.
RT – PCR analyses in normal and cancerous breast tissues
The expression patterns of two kallikreins were further verified for
KLK5, 6, 8, 10, 12 and 15 by RT–PCR analysis in histologically
confirmed normal (N¼4) and cancerous (N¼14) breast tissues.
As shown in Figure 1, while KLK5 was expressed at high levels in
all four normal breast tissues, it was only detectable in three out of
14 cancerous breast tissues examined. KLK6 was strongly positive
in normal breast tissue, but was not expressed in nine out of 14
tumour tissues, lower than normal in three and compared to
normal in two (data not shown). KLK8 also showed a strong band
in normal tissues, compared to undetectable expression in five
tumour tissues, lower than normal in seven tumours and
compared to or more than normal in two (Figure 2A). KLK10
showed no expression in eight tumours, lower than normal in five
and compared to normal in one tumour (Figure 2). Figure 3 shows
that while KLK12 was detectable in three out of four normal breast
tissues, it was expressed at relatively lower levels in six out of 14
cancers. We also analysed KLK15 expression (as a negative control
with no expression difference by in silico analysis), and found no
difference in expression between normal and breast tumour tissues
(data not shown).
DISCUSSION
Our results indicate that at least four kallikrein genes are
downregulated in breast cancer. These data are consistent with
earlier reports indicating differential expression of kallikreins in
breast cancer (Diamandis and Yousef, 2001; Diamandis and
Yousef, 2002; Yousef and Diamandis, 2002a). The KLK10 gene
(previously known as normal epithelial cell-specific gene 1, NES1)
was originally cloned by subtractive hybridisation based on its
downregulation during oncogenic transformation of human
mammary epithelial cells (Liu et al, 1996). More recently, it was
suggested to have tumour suppressor activity (Goyal et al, 1998).
Using a highly sensitive and specific immunoassay, we found hK10
expression in normal breast and in milk of lactating women (Luo
et al, 2001b). hK10 was also found to be a potential marker for
other malignancies, like testicular and ovarian cancers (Luo et al,
2001a, c, 2003). Recently, Band and colleagues have shown, using
in situ hybridisation, lower levels of KLK10 expression in breast
cancer cells when compared to normal cells (Dhar et al, 2001).
Our results with different tools (SAGE, EST and X-profiler) were
consistent for KLK5, 6 and 10. The results for KLK3, however, were
not clear cut. Whereas the SAGE data showed a slight down-
regulation in cancer compared to normal, the EST and DDD results
indicate an overexpression in breast cancer. Neither of the above
results was robust enough to draw a conclusion. The SAGE data
were obtained from only one library and the level of expression
was ‘low’. The EST data were also only two clones from one library.
In addition, some of the libraries used for DDD were normalised or
subtracted, thus reducing the quantitative meaning of the results.
This apparent discrepancy might be due to the overall low
expression levels of KLK3 in the breast, leading to undetectable
transcripts in many libraries. Earlier, it was reported that KLK3
(PSA) is not prostate specific and that it is also expressed in many
other tissues including the female breast, albeit at much lower
concentrations (Black and Diamandis, 2000). The potential
prognostic importance of hK3 expression in breast cancer has
also been reported (Yu et al, 1995).
Significant differences in expression levels were obtained for
KLK12, especially when comparing the normal and cancer pools
(Table 5). These results follow the general pattern of down-
regulation of kallikreins in breast cancer. Our previous results
indicate moderate KLK11 mRNA expression in the normal
mammary gland (Yousef et al, 2000c). We have also previously
shown that KLK5 mRNA is highly expressed in normal breast
tissue (Yousef and Diamandis, 1999) and found potential
prognostic significance of KLK5 expression in breast cancer
(Yousef et al, 2002; 2003).
The KLK6 gene (previously known as zyme, protease M,
neurosin, PRSS6) was originally cloned based on its lower
expression in metastatic breast cancer compared to primary
cancer and normal tissue (Anisowicz et al, 1996). In this study, the
mRNA was detectable in one out of two normal cell lines, two out
of three primary breast cancer and one out of nine metastatic
breast cancer cell lines. Considering the small sample number in
the previous study, it was difficult to draw a definite conclusion
about the expression of this gene in different phases of cancer.
Nacht et al have recently used a novel approach of combining
SAGE analysis with array technology to find genes differentially
expressed in breast cancer (Nacht et al, 1999). Comparing one
normal cell line vs two primary tumour cell lines, they identified
KLK6 as one of the differentially expressed genes between normal
and primary breast cancer (a 2.4-fold increase in cancer). It is
possible that these results reflect an individualised behaviour of
certain cancer cell line. Our results have the advantage of
comparing pools of normal and cancerous tissues, rather than
individual cell lines. In a more recent analysis by Seth et al,
M T1 T2 T3 T4 T5 T6 T8 T9 T10 T11 T12 T13 T14 N1 N2 N3 N4 T7
KLK5
Actin
Figure 1 Expression of the KLK5 gene in breast tumour (T1–T14) and normal (N1–N4) tissues. While high-expression levels were detectable in all
normal tissues, the gene was expressed in only three out of 14 cancerous tissues. Actin, a house-keeping gene, was used as a control. M, molecular weight
marker.
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ykallikreins 5 and 6 were identified among 35 transcripts that were
most abundantly expressed in oestrogen receptor (ER)-positive
normal human breast tissue (Seth et al, 2002). Interestingly,
comparing their constructed SAGE library tags with other normal,
in situ, invasive and metastatic carcinoma tags from different
SAGE libraries, their data indicate that these two kallikreins are
exclusively expressed in normal breast tissues (Seth et al, 2002).
The hK6 protein was recently shown to be a potential marker for
ovarian cancer (Diamandis et al, 2003). Also, in a recent analysis,
the median serum concentration of hK6 was found to be higher in
normal females (median expression of 7.0mgl
 1) compared to
breast cancer patients (median expression of 4.3mgl
 1) (Diaman-
dis et al, 2000a). In addition, the hK6 protein was found at high
concentrations in breast tissue, milk of lactating women, nipple
aspirate fluid and breast cyst fluid, with lower levels detectable in
breast tumour cytosols (Diamandis et al, 2000b).
A noteworthy observation is the presence of a group of closely
localised kallikreins (KLK5, 6, 8, 10, 11 and 14) with a similar
pattern of differential expression in breast cancer. This points to
the possibility of the existence of a locus control region or another
common regulatory mechanism that controls the parallel expres-
sion of these kallikreins.
Other kallikrein genes, for example, KLK13 and KLK14, were
also previously reported to be downregulated in breast cancer
(Yousef et al, 2000a, b, 2001). Our analyses did not show any
detectable expression of these genes by either SAGE or EST
methods. This is likely due to the fact that these genes are
expressed in the breast at very low levels that are not detectable,
except by sensitive techniques like RT – PCR.
It should be emphasised that although in silico analysis is a
useful research method, the results should be verified by more
than one analytical tool, and further experimentally confirmed.
Possible sources of bias include sequence errors, presence of
specific sequence mutations associated with certain malignancies,
unequal presentation of different physiological or pathological
libraries and the expression of splice variants in certain
malignancies.
Lercher et al, during global analysis of over 11000 genes in 14
different tissues, have set a cut-off value for gene expression as
being low (p37tpm) and intermediate or high (X134tpm)
(Lercher et al, 2002). If this cut-off is to be applied to our data,
we can conclude that while kallikrein gene expression is absent or
low in breast cancer, medium-to-high levels of expression are
found in the normal breast.
Several hypotheses can be proposed regarding the possible
mechanism(s) by which kallikreins may be involved in cancer.
KLK3 was previously shown to have an antiangiogenic and a
tumour suppressor effect on the growth of some breast cancer cell
lines (Lai et al, 1996; Fortier et al, 1999). Breast cancer is a
‘hormonal’ malignancy. Kallikreins, being under steroid hormone
regulation, may represent downstream targets by which hormones
influence the initiation or progression of cancer. Another possible
mechanism for the involvement of kallikreins in malignancy is the
activation of proteinase-activated receptors (PAR). The activation
of these receptors elicits different responses in several tissues.
It is important to mention that mRNA levels might not be
necessarily be associated with a decrease in the serum or tissue
levels of these proteins. As is the case with hK3, the serum rise
might be due to ‘leakage’ from malignant cells due to architectural
and angiogenic changes. We have recently shown elevation of hK5
levels in the serum of some patients with breast cancer (Yousef
et al, 2003).
In conclusion, we provide strong evidence suggesting that at
least four kallikreins are downregulated in breast cancer. These
data were confirmed from several databases and by experimental
analysis with RT – PCR. It will be useful to examine these
kallikreins as biomarkers for diagnosis, prognosis and treatment
decisions in breast cancer.
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M T1 T2 T3 T4 T5 T6 T8 T9 T10 T11 T12 T13 T14 N1 N2 N3 N4 T7
Figure 3 Expression of the KLK12 gene in breast tumour (T1–T14) and normal (N1–N4) tissues. Actin, a house-keeping gene, was used as a control. M,
molecular weight marker.
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